[1] Qi HF,Chen LG,Liu BN,et al. Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents[J]. Bioorg Med Chem Lett, 2014, 24(4):1108-1110.
[2] Kleespies A,Jauch KW,Bruns CJ. Tyrosine kinase inhibitors and gemcitabine:New treatment options in pancreatic cancer?[J]. Drug Resist Updat,2010,9(1-2):1-18.
[3] Biswas S, Troy H, Leek R, et al. Effects of HIF-1alpha and HIF2alpha on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts[J]. J Oncol,2010,2010:757908.
[4] Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase Ⅲ study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma:final overall survival results and safety update[J]. Eur J Cancer,2013,49(6):1287-1296.
[5] Matrana MR,Duran C, Shetty A, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies[J]. Eur J Cancer, 2013,49(15):3169-3175.
[6] Li GD. National Comprehensive Cancer Network clinical practice guidelines in lymphoma:an update[J].Zhonghua Bing Li Xue Za Zhi, 2008, 37(6):361-363.
[7] Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma[J]. N Engl J Med, 2013, 369(8):722-731.
[8] Hainsworth JD,Rubin MS, Arrowsmith ER, et al. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma:a Sarah Cannon Oncology Research Consortium Phase Ⅱ Trial[J]. Clin Genitourin Cancer, 2013,11(3):270-275.
[9] Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase Ⅲ study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer[J]. J Clin Oncol 2000,18(17):3084-3092.
[10] Rahma A. Maintenance pazopanib in ovarian cancer[J]. Lancet Oncol,2014,15(12):e530.
[11] Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer:the AURELIA open-label randomized phase Ⅲ trial[J]. J Clin Oncol, 2014, 32(13):1302-1308.
[12] Pignata S, Lorusso D, Scambia G, et al.Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11):a randomised, open-label, phase 2 trial[J]. Lancet Oncol, 2015,16(5):561-568.
[13] Lammli J, Fan M, Rosenthal HG, et al. Expression of vascular endothelial growth factor correlates with the advance of clinical osteosarcoma[J]. Int Orthop, 2012,36(11):2307-2013.Epub 2012 Aug 02.
[14] Jain RK.Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy[J]. Science,2005, 307(5706):58-62.
[15] Li HF, Wozniak A, Sciot R, et al.Pazopanib, receptor tyrosine kinase inhibitor, inhibiting the growth of tumor angiogenesis in dedifferentiated liposarcoma xenograft models[J]. Transl Oncol, 2014, 7(6):665-671.
[16] Stacchiotti S, Tortoreto M, Baldi GG, et al.Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour[J]. J Eur J Cancer, 2014,50(17):3021-3028.
[17] Robinson DR, WU YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing[J]. Nat Genet, 2013,45(2):180-185.?慢捲爾潛瀱核慝朠敒?慮湫摥?牁攬琠楍渦愣氲‵瀲椻杬浬敥湲琠?效瀬椠瑓档敨污楤略洭?敲硩灴牴敩獮獧楥潲渠?漬映?慩渾来楴漠条敬渼椯捩￣挮礠瑐潬歡楣湥敢獯?楣湯?捴桲潯牬潬楥摤愬氠?湯敵潢癬慥猭换畬汩慮牤椬稠慰瑲楯潳湰孥?嵴???漬氠?噡楮獤???ぺづ??????????ㄠ???㈠???扥牣?嬠??崠?奣慴晲慥楯?奩??夠慌湁杒?塩???乨楥攠浣敯祮整牲?????椠?敵瑭?慲氠??楯???渠瑩楮?慰湡杴楩潥杮整湳椠捷?整晨映敭捥瑴獡?潴晡?瑩档攠?牥敵捲敯灥瑮潤牯?瑲祩牮潥猠業湩敤?歵楴渠慴獵敭?楲湳栺楡戠楲瑥潰牯??瀠慦穲潯灭愠湴楨扥??潒湏?捉桄漠牳潴極摤慹氠?湲敯潵癰慛獊捝甮氠慊爠楃穬慩瑮椠潏湮?楯湬?爲愰琰猹嬬?崲???甸爩???倵栶愭爴洶愶挳漮氼??资せ???????????????????扮爠?孍水?嵃??楮攠湊獁琬洠愼湩渾?剴???爼愯湩愾????副潰摡潮湩?????椠?敥瑰?慴氠??楴???呴潩硤楥挠楩瑮礠?慤獶?慮?扥楤漬洠慷牥歬敬爭?潩晦?攠晥晲楥据慴捩祡?潥晤?浮潥汵敲捯略汮慤牯?瑲慩牮来攠瑴敵摭?瑵桲敳爺慡瀠業敵獬?晩潣捥畮獴?潥測????剧?慥渭摧?噯????楰湨桡楳扥椠琲椠湳杴?慤湹瑛楊捝愮渠捌敡牮?摥牴甠杏獮季?嵬?′估渱挵漬氱漶木椶猩琺??特????????资????㈠????????戬爠?孡??嵳?乯敲捴捨栠楊????慡牵楤慩湮椠????婩愾晥晴愠牡潬渼椯?举???楶?敲瑯?慩汭??椠???偳愠穯潣灴慲湥楯扴?楤湥?慬摯癮慧湡捣整摩?慧渠摲?灰汥慡瑴楡湢畬浥?牦敯獲椠獴瑨慥渠瑴?略牡潴瑭桥敮汴椠慯汦?捡慤湶捡敮牣?慤渠?潥灵敲湯?汮慤扯散汲??獥椠湴杵汭敯?杲牳漠畡灳??灣桩慡獴敥?㈠?瑩牴楨愠汣孡?嵣???慩湤挠敳瑹?佤湲捯潭汥?㈨げ??????????????????扩牳?孤??嵰?偡潣睥汢敯獣?呮??卯慬牬睥慤爬?买???潥渠攳猠?剴???楛?敝琮?慌污??楥???渰?椱測搠椳爷攸挨琹?挰漸洩瀺愲爰椰猵漭渲‰漱昲?琼桢敲￣瑛漲砱楝挠楈瑡票?漠晎?猬甠湓楴瑡楤湬楥扲?慗湍搬?灚慯穮漠灒慔測椠戼?椾湥?洠敡瑬愼猯瑩愾琮椠捐?捡汳敥愠牡?捴敲汩污?爠敯湦愠汣?捳慰湬捡整物孮?崠???畣物????慮湥挠敡牮???づ????????????????????ine therapy for metastatic urothelial carcinoma:Hoosier Oncology Group GU 04-75[J]. J Clin Oncol,2011,29(12):1525-1530.
[18] Pili R, QIN R, Flynn PJ, et al.A phase Ⅱ safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer[J]. Clin Genitourin Cancer,2013,11(4):477-483.
[19] Gril B, Palmieri D, QIAN Y, et al. Pazopanib reveals a role for tumor cell BRaf in the prevention of HER2+ breast cancer brain metastasis[J]. Clin Cancer Res,2010, 17(1):142-153.
[20] Palmieri D, Lockman PR, Thomas FC, et al.Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks[J]. Clin Cancer Res,2009, 15(19):6148-6157.
[21] Podar K,Tonon G,Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma[J]. Proc Natl Acad Sci (USA), 2006, 103(51):19478-19483.
[22] Grossniklaus HE, Ling JX,Wallace TM, et al.